Sign in
GRAY Stock Price, Chart, Stats & News
Graybug Vision, Inc.
Save
Graybug Vision, Inc. (GRAY) does not currently pay a dividend.
120.98M
Market cap
–
Current P/E
–
Forward P/E
GRAY chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -217.51% |
ROE | -1172.86% |
D/E | – |
Interest coverage ratio | -29.95x |
GRAY valuation
P/E | – |
P/S | – |
P/B | -12.43x |
P/CF | -3.90x |
P/FCF | -5.71x |
P/OCF | -3.90x |
PEG | 0.02x |
EV multiple | -5.31x |
About
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema.
Similar securities
Based on sector and market capitalization
Report issue